Similar to TNFs, ILs do not always promote immune responses, but they can regulate immune cell activity; thus, IL-2 can be used for SLE treatment, as well as IL-12 and IL-17, which are promising therapeutic targets, as well as potential biomarkers of disease activity [34–36]. This evidence concerns the gene IL17A and systemic lupus erythematosus.